You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》石藥集團(01093.HK)全年純利58.73億元人民幣跌3.6% 派末期息14港仙
阿思達克 03-20 12:07
石藥集團(01093.HK)公布截至去年12月底止全年業績,營業額314.5億元人民幣(下同),按年升1.7%。毛利率下降1.4個百分點至70.5%,主要是由於收入結構變化及維生素C產品銷售價格下降所致。純利58.73億元,按年跌3.6%;每股盈利49.47分。派末期息14港仙,上年同期派11港仙。連同中期股息,全年股息28港仙,而上年同期為21港仙。 期內,撇除按公平值計入損益之金融資產之公平值變動、以股份為基礎之僱員酬金開支及視作出售聯營公司及合營企業部分權益之收益,股東應佔基本溢利為62.75億元,較2022年增加2.8%。 成藥業務收入為256.37億元,較去年同期增加4.6%;原料產品收入減少9.7%至36.41億元;功能食品及其它收入跌8.9%至21.72億元。 集團去年研發費用48.3億元,按年增加21.2%,約佔成藥業務收入18.8%。目前公司逾60個重點在研藥物已進入臨床或申報階段,其中7個已遞交上市申請,18個處於註冊臨床階段。目前集團在研創的新藥項目約130項,其中大分子40餘項、小分子40餘項、新型製劑30餘項,預計未來5年將有近50款創新藥申報上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account